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Abstract
In our effort to develop selective sphingosine kinase-2 (SphK2) inhibitors as pharmacological tools, a thiazolidine-2,4-dione
analogue, 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145), was synthesized and bio-
logically characterized. Biochemical assay results indicate that K145 is a selective SphK2 inhibitor. Molecular modeling
studies also support this notion. In vitro studies using human leukemia U937 cells demonstrated that K145 accumulates in
U937 cells, suppresses the S1P level, and inhibits SphK2. K145 also exhibited inhibitory effects on the growth of U937 cells as
well as apoptotic effects in U937 cells, and that these effects may be through the inhibition of down-stream ERK and Akt
signaling pathways. K145 also significantly inhibited the growth of U937 tumors in nude mice by both intraperitoneal and
oral administration, thus demonstrating its in vivo efficacy as a potential lead anticancer agent. The antitumor activity of
K145 was also confirmed in a syngeneic mouse model by implanting murine breast cancer JC cells in BALB/c mice.
Collectively, these results strongly encourage further optimization of K145 as a novel lead compound for development of
more potent and selective SphK2 inhibitors.
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Introduction
Sphingosine-1-phosphate (S1P), a lipid metabolite, has been
recently demonstrated to be an important signaling mediator for
vital cellular and physiological processes, such as cell motility,
invasion, proliferation, angiogenesis and apoptosis [1,2]. S1P is
produced from sphingosine via phosphorylation by two isoen-
zymes, sphingosine kinase-1 (SphK1) [3] and sphingosine kinase-2
(SphK2) [4]. Upon production, S1P interacts with a family of G
protein-coupled receptors (S1PR1–5) on the cell surface [5] and/or
intracellular targets, such as histone deacetylase (HDAC) [6] and
TRAF2 [7], to play a plethora of roles in diverse pathophysio-
logical conditions such as inflammation, immunity and cancer.
Ceramide and sphingosine, the precursors of S1P, have been
associated with growth arrest and apoptosis [8]. In contrast, S1P
has been demonstrated to play pro-survival roles [9]. The
regulation of the levels of these metabolites, a so called
‘‘sphingolipid rheostat’’ [1,9], is complex and a number of
enzymes have been demonstrated to be important [2,8], among
which SphK1 and SphK2 have emerged as central players [2,10].
Although SphK1 and SphK2 share a high degree of homology,
they differ significantly in size, tissue distribution, and subcellular
localization [11]. For example, SphK1 mainly resides in the
cytosol [12] while SphK2 is present in several intracellular
compartments, mainly in the nucleus, endoplasmic reticulum,
and mitochondria [13]. Evidence has accumulated that SphK1
promotes cell growth and survival, and has been associated with
many aspects of cancer development and progression, such as
proliferation, migration, invasion and angiogenesis [14]. Consis-
tent with this, numerous studies have shown that SphK1 is
frequently up-regulated and/or overexpressed in tumor tissues
compared to normal tissues [15]. Much less is known about
SphK2. Initially, SphK2 had been demonstrated to be pro-
apoptotic as overexpression of SphK2 suppresses growth and
promotes apoptosis [16]. However, it was subsequently shown that
downregulation of SphK2 inhibits the proliferation and migration
of tumor cells, such as glioblastoma and breast cancer cells [17,18]
and ablation of SphK2 or employing a SphK2 inhibitor has been
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shown to inhibit the xenograft growth of tumor cells in mice
[15,19,20]. Recently, HDAC has been identified as an intracel-
lular target of S1P, which is mainly produced by SphK2 within the
nucleus and indicates a potential role of SphK2 in histone
acetylation, gene expression, and cancer pathology [6]. SphK2 has
also been demonstrated to play important roles in the function of
mitochondria [21]. Even with these very recent advances in
understanding of SphK2, much is still unknown or controversial
about this kinase. Therefore, development of selective SphK2
inhibitors would be of great value as pharmacological tools to
complement the ongoing molecular and genetic studies, and help
unravel the roles of SphK2 in different pathological and
physiological conditions. Although a number of potent and
selective SphK1 inhibitors have been developed and reported
[2,22–24], only a few SphK2 inhibitors with moderate potency,
such as ABC 294640 (1) [19], SG-12 (2) [25], R-FTY720-OMe (3)
[26] and trans-12 (4) [27], have been reported (Figure 1).
Therefore, it would be of great value to have new and adaptable
chemical scaffolds available as selective SphK2 inhibitors as this
would help unravel the structural requirements for designing new
SphK2 inhibitors.
Recently, our research group has initiated development of 3-(2-
amino-ethyl)-thiazolidine-2,4-dione (TZD) analogues (5, Figure 2)
as dual-pathway inhibitors of the ERK and Akt signaling pathways
[28,29]. However, the cellular target(s) of these dual-pathway
inhibitors remain unknown. Although the rhodanine- and TZD-
compound types have been referred to as Pan Assay INterference
compounds (PAINs) because of their frequent appearance as hits
suggesting promiscuity [30], rhodanine and TZD analogues have
also been recognized as privileged templates in drug design and
discovery [31]. Recently, studies have also suggested that distinct,
not nonsepecific, interactions exist between them and biomacro-
molecules, and that these scaffolds should not be regarded as
promiscuous binders, although diligence in examining selectivity
for moderate affinity compounds with these functional groups is
advised [32]. Numerous compounds containing the TZD ring
have already been developed as potential anticancer agents, such
as the PI3K inhibitor GSK1059615 and its analogues [33].
In comparing it to sphingosine (6), the 3-(2-amino-ethyl)-TZD
moiety of our dual-pathway inhibitors may be able to mimic the
amino-hydroxyl sphingoid base. Furthermore, SphK inhibitors
have been shown to inhibit the ERK and Akt signaling pathways
as a downstream event of SphK inhibition [10,23,24]. These
observations suggested to us that SphKs might be protein targets
of the TZD-based dual-pathway inhibitors. Furthermore, previous
studies suggested that a phenyl ring with an alkyl chain is an
important structural feature as SphK inhibitors [24]. Therefore,
we report herein the design and biological characterization of
K145, 3-(amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thia-
zolidine-2,4-dione (7, Figure 2) as a selective SphK2 inhibitor.
Results and Discussion
Chemistry
The synthesis of K145 is shown in Figure 3. Briefly, 3-(4-
butoxy-phenyl)-propionaldehyde (10) was prepared from 4-
butoxy-benzaldehyde (8) by reacting with Meldrum’s acid in the
presence of piperidine followed by reduction [29]. Then, the
condensation reaction of 10 with 13, prepared from thiazolidine-
2,4-dione, followed by the removal of the Boc protecting group
afforded K145 in good yield.
In vitro Studies
After synthesis, we first examined the effects of K145 on
recombinant SphK1 and SphK2. Notably, K145 inhibited the
activity of SphK2 in a dose-dependent manner with an IC50 of
4.3060.06 mM (Figure 4A), while no inhibition of SphK1 at
concentrations up to 10 mM was observed. In contrast, and as
expected, DMS (10 mM), a non-selective SphK inhibitor, inhibited
both SphK1 and SphK2. Thus, K145 is a selective SphK2
inhibitor. Lineweaver-Burk analysis revealed a Ki of 6.460.7 mM
for SphK2 and indicated that K145 is a substrate competitive
inhibitor (with sphingosine) (Figure 4B). The overlay of K145 with
sphingosine also supports these results (Figure 4C). Since K145 is a
sphingosine analogue, we then tested it against ceramide kinase
(CERK) to confirm selectivity. As shown in Figure 4D, at a
concentration up to 10 mM, no significant inhibition of CERK was
observed. Further screening against eleven other protein kinases
(Figure 4E) also demonstrated the relative selectivity of K145 to
SphK2.
Next we examined whether K145 affects cellular levels of S1P.
Human leukemia U937 cells have been demonstrated to be a good
model to test compounds that interfere with the SphK/S1P system
and it has previously been shown that S1P is protective against
apoptosis of U937 cells [9,23,24,34]. Therefore, we further
characterized K145 in U937 cells. As shown in Figure 5A,
K145 is readily taken up by U937 cells in a concentration
dependent manner. In agreement with its ability to inhibit SphK2,
Figure 1. Chemical structures of SphK2 inhibitors.
doi:10.1371/journal.pone.0056471.g001
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but not ceramide kinase (Figure 4D), as shown in Figures 5B and
5C, treatment with K145 (10 mM) caused a decrease of total
cellular S1P without significant effects on ceramide levels. The
inhibitory potency of K145 on cellular level of S1P is somewhat
less than its IC50 (4.3 mM) determined at recombinant SphK2.
This might be due to the fact that many enzymes such as SphK1,
SphK2, S1P lyase, and S1P phosphatise, not just SphK2, are
involved in the regulation of cellular S1P. The level of ceramide-1-
phosphate (C1P) was not significantly affected upon treatment
with K145 (10 mM, Figure 5D), which indicates that K145 does
not interfere with CERK and/or ceramide synthase, consistent
with the results from recombinant CERK studies. To further
confirm its SphK2 selectivity, we then tested the effects of K145
on the phosphorylation of FTY720, a SphK2 specific substrate
[35]. As shown in Figure 5E, K145 inhibited the phosphorylation
of FTY720, which further indicates the SphK2 specificity of
K145. SphK2 inhibitors have been shown to have anti-prolifer-
ative activities in cancer models both in vitro and in vivo [19,20].
SphK2 has also been recently shown to play a role in
mitochondria function and apoptosis. Therefore, we tested the
anti-proliferative and apoptotic effects of K145 in U937 cells. As
shown in Figure 6A, K145 significantly inhibited the growth of
U937 cells cultured in the presence of 10% serum in a
concentration-dependent manner. In agreement with our study,
others using a different SphK2 inhibitor ABC294660 [20], or
downregulation of SphK2 [15] also observed effects on cell
proliferation, while treatment with another SphK2 inhibitor
SLR08081 caused only a small decrease in cell viability [36].
K145 also significantly induced apoptosis in U937 cells under
these experimental conditions (Figure 6B). Notably, K145 induced
mainly late apoptosis with a very small percentage of necrotic cells
after 24 h treatment in the presence of 10% serum. In contrast, the
SphK1 inhibitor SK1-I mainly induced early apoptosis of U937
cells after similar treatment (24 h in the presence of 10% serum)
[24]. This suggests that SphK1 and SphK2 may have different
roles in the regulation of apoptosis, at least for U937 cells.
S1P has been shown to activate the downstream ERK and Akt
signaling pathways [37,38] and these two signalling cascades have
been demonstrated to cooperatively link with each other to
regulate apoptosis and the survival of transformed cells including
human leukaemia cells [39]. As shown in Figure 6C, phosphor-
ylated ERK and Akt were decreased by treatment of U937 cells
Figure 2. Chemical structures of dual-pathway inhibitors, sphingosine, and K145.
doi:10.1371/journal.pone.0056471.g002
Figure 3. Chemical synthesis of K145.
doi:10.1371/journal.pone.0056471.g003
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with K145, consistent with our previous results with TZD
analogues as dual-pathway inhibitors [28,29]. Notably, the
inhibition of these two signaling pathways is evident at as low as
4 mM of K145, consistent with its IC50 values of SphK2 inhibition
and anti-proliferation of U937 cells. Studies have demonstrated
the synergistic effects in triggering cancer cell death by concom-
itant interruption of these two pathways, both in vitro and in vivo
using a combination regimen [40]. The simultaneously inhibitory
effects of K145 on ERK and Akt pathways upon its inhibition of
SphK2 may explain its significant anti-proliferative and apoptotic
effects in U937 cells.
Molecular Modeling
To further understand the SphK2 selectivity of K145, we
conducted molecular modeling studies to identify the structural
features of K145 that interact with key residues of SphK2. Since
no crystal structure is currently available for either SphK1 or
SphK2, we generated structural models of SphK1 and SphK2
using MODELLER [41]. a comparative protein structure
modeling program, using the structure of Diacylglycerol kinase
from Bascillus anthracis str. Sterne (PDB ID: 3T5P) as a template
[42,43]. The overall structural geometries of the resulting models
were checked using MOLPROBITY [44] (clash scores for both
proteins .97th percentile) and the Ramachandran plots for the
backbone conformations showed .96% of residues in allowed
regions for both isoforms. Despite low overall homology to the
template (,46% in aligned regions for both isoforms), there is
considerable sequence and structural similarity at the sphingosine-
binding (C4) domain [45], and we believe that these models
provide valuable structural information.
The final optimized models for both proteins were validated
with a panel of inhibitors including the reported SphK2 inhibitors
shown in Figure 1, a SphK1 selective inhibitor, SK1-I [24], and
FTY720, a compound known to bind to both SphKs [46,47]. The
Figure 4. K145 inhibits SphK2 but not SphK1. A) SphK1 and SphK2 activities were measured with 5 mM sphingosine in the absence or presence
of the indicated concentrations of K145 or 10 mM DMS. Data are expressed as percentage SphK activity in the absence of inhibitor; B) SphK2 activity
was measured with increasing concentrations of sphingosine and the indicated concentrations of K145. Lineweaver-Burk analysis revealed a Vmax of
108206210 pmol/min per mg of protein, and a Ki of 6.460.7 mM for SphK2; C) Overlay of K145 with sphingosine; D) CERK activities were measured
with 12.5 mM ceramide in the absence or presence of the indicated concentrations of K145 or 100 mM of DMS and sphingosine; E) Effect of K145
(10 mM) on activity of the indicated enzymes was tested by SelectScreen Kinase Profiling from Invitrogen. Data are expressed as percentage of control
activity averaged from 2 independent experiments. Data are expressed as mean value 6 SEM.
doi:10.1371/journal.pone.0056471.g004
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binding sites for SphK2 and SphK1 were defined to encompass all
atoms within 20 A˚ of the CA of Asp344 and Asp178, respectively.
Docked poses were generated using GOLD [48] v5.1 and rescored
using HINT [49]. The best scoring docked positions for each
ligand were selected for minimization (2500 iterations, termination
gradient of 0.005 kcal/mol-A˚). As shown in Table 1, the relative
ordering of HINT scores (HTOT) are largely in concordance with
the reported binding/inhibitory observations (Table 1). [50,24–
27].
We then docked K145 to the two kinase models. The docking
results revealed that K145 binds preferentially to SphK2 (Table 1).
Specifically, as shown in Figure 7, our model indicates that the
terminal –NH2 of K145 forms strong H-bond interactions with
the carboxylate group of Asp344 (the putative sphingosine
recognizing residue). Other favourable hydrogen bonding inter-
actions are also formed between the guanidino-group of Arg351
and Gln346 with the carbonyl oxygens of the TZD heterocycle.
The TZD ring of K145 shows favourable p-stacking interactions
with Phe350 and the 4-butoxy-phenyl ring of K145 fits into a
hydrophobic pocket that consists of Ala336, Val340, Val343,
Arg617 and Val619. K145 showed a very similar binding mode
within the sphingosine-binding pocket of SphK1 except that, in
contrast to its binding mode in SphK2, the carbonyl oxygen at the
4-position of the TZD ring (interacting with Gln346 in SphK2)
showed unfavourable base/base interactions with the carboxylate
group of Glu180 (corresponding to SphK2/Gln346). Judging from
the sequence similarity in the sphingosine-binding domains of both
isoforms, the Gln RGlu change in SphK1 is the only significant
difference in this region and might be the reason for K145
showing selectivity towards SphK2.
In vivo Studies
Downregulation of SphK2 or application of a SphK2 inhibitor
have shown anti-tumor effects both in vitro and in vivo [15–20] and
we have shown the anti-proliferative and apoptotic effects of K145
in U937 cells; thus, we evaluated the ability of K145 to inhibit the
growth of U937 tumors in nude mice. Tamibarotene [51], a
retinoid compound that has been approved for acute promyelo-
cytic leukemia in Japan, was used as a positive control. Both
tamibarotene and K145 were given at a 15 mg/kg dose by i.p.
injection. As shown in Figure 8A, K145 significantly inhibited the
Figure 5. K145 accumulates and suppresses the S1P level. A and B) U937 cells were treated with K145 at the indicated concentrations for 3 h
and the levels of K145 and S1P were measured by ESI-MS/MS. C) HEK293 cells were treated with K145 (10 mM) for 2 h. Lipids were extracted and
different chain length species of ceramide were determined by LC-ESI-MS/MS. Numbers indicate chain length followed by the number of double
bonds in the fatty acid. Data are averages of triplicate determinations and are expressed as pmol lipid/106 cells. D) U937 cells were treated with or
without K145 (10 mM) for 3 h and levels of C1P species were determined by ESI-MS/MS. E) U937 cells were treated with FTY720 (1 mM) in the absence
or presence of indicated K145 for 3 h, then FTY720-P was measured by ESI-MS/MS. *P,0.05 compared to control.
doi:10.1371/journal.pone.0056471.g005
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growth of U937 tumors in nude mice with a TGI of 44.2%,
slightly less potent than tamibarotene (TGI = 50.4%) after 17 days
treatment. This is also reflected by the tumor weights of treatment
groups (Figure 8B). The tumor growth curve during the treatment
course (Figure 8C) also attests to the anti-tumor effects of K145 in
this model. Lastly, as shown in Figure 8D, the body weights of
K145-treated mice remained the same as that of vehicle-treated
mice, while tamibarotene treatment caused body weight decreases
in the mice. These results strongly suggest that K145 exhibits
comparable in vivo anti-tumor activity to tamibarotene, while
concomitantly exhibiting less toxicity in this U937 xenograft
cancer model.
On the basis of this in vivo anti-tumor activity in nude mice, we
attempted to further confirm K145’s in vivo anti-tumor activity
using a syngeneic breast cancer model. In this regard, we selected
a tumor model that uses the mouse JC mammary adenocarcinoma
cell line growing subcutaneously in immunocompetent BALB/c
mice [19,52]. Since K145 demonstrated in vivo activities at
15 mg/kg dose in the nude mice experiment, we used two doses,
20 mg/kg and 35 mg/kg through i.p. injection in this model. As
illustrated in Figure 9A, treatment of BALB/c mice (n = 8) bearing
the JC xenograft significantly inhibited tumor growth at both doses
with the higher dose being more potent. After 15 days treatment,
the mean volume of the JC tumors in the treated-mice at both
doses was .50% smaller than that in the vehicle-treated mice.
Tumor weights of K145-treated mice were also significantly less
than that in vehicle-treated mice in a dose-dependent manner
(Figure 9B). Post-experiment visual evaluation of the tumor
samples also confirms the results (Figure 9D). We analyzed the
tumor samples to detect K145, the change of S1P by ESI-MS/MS
and the change of signaling pathways by Western blot. As shown
in Figure 9C, K145 was detected in JC tumors and the S1P level
was suppressed compared to vehicle, consistent with the results
from U937 cells assays. Notably, the p-ERK and p-Akt levels were
Figure 6. K145 exhibits antiproliferative and apoptotic effects in U937 cells. A) U937 cells were treated with K145 at indicated
concentrations for indicated intervals, the cell viability was determined by MTT assay; B) U937 cells were treated with K145 (10 mM) for 24 h, then the
cells were stained with Annexin V/PI and analyzed by flow cytometry; C) U937 cells were treated with K145 at indicated concentrations for 3 h, after
which cell lysates were analyzed by Western blot using corresponding primary antibodies. The image of Western blot represents the results from one
of two independent experiments. Data are expressed as mean value 6 SEM.
doi:10.1371/journal.pone.0056471.g006
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decreased in the tumor samples compared to the vehicle controls
(Figure 9E), which is consistent with the results from U937 cells
(Figure 6C). We did not observe significant changes in body
weights and the major organs, such as heart, lung, liver and kidney
(data not shown), thus indicating a lack of general toxicity of
K145.
Lastly, we examined the anticancer activity of K145 to inhibit
the tumor growth of U937 cells in nude mice (BALB/c-nu) by oral
administration to investigate whether it is orally available. In this
experiment, K145 was given at 50 mg/kg by oral gavage daily for
15 days and tumor volume and animal weights were measured
every other day. Again, tamibarotene (20 mg/kg) was used as
positive control. As shown in Figure 10A, tumor weights of K145-
treated mice were significantly less than that in vehicle-treated
mice and K145 exhibited better antitumor activity than tamibar-
otene at tested doses by oral administration (TGI for K145 and
tamibarotene are 51.25% and 33.37%, respectively). Visual
examination of the tumor samples also confirmed the significant
inhibition of U937 tumor growth by K145 (Figure 10B). Tumor
growth curve also demonstrated the superior anti-tumour activity
of K145 in these experimental settings (Figure 10C). As shown in
Figure 10D, at the beginning of the treatment, there was a slight
decrease of body weights in K145-treated group but the body
weights of this group came back in the remaining course of the
study. Collectively, the results of in vivo studies with K145 by oral
administration demonstrated that K145 is orally available to
inhibit the growth of U937 tumors at 50 mg/kg dose and no
apparent toxicity was observed, which is consistent with the results
from in vivo studies by i.p. injection administration. To summa-
rize, all in vivo results we have obtained strongly suggest that K145
has in vivo anti-tumor activity, thus it may serve as a good lead
compound for development of more potent and selective SphK2
inhibitors and new anticancer agents.
Conclusions
K145 was identified as a selective SphK2 inhibitor. Biochemical
assays using recombinant SphK1 and SphK2 established that
K145 selectively inhibited SphK2 but not SphK1. Molecular
modeling and docking studies also suggested that K145 favorably
binds to SphK2 but not SphK1 within their respective sphingosine
binding pockets, consistent with the biochemical assay results.
Further biological characterization using human leukemia U937
cells demonstrated that K145 accumulated in U937 cells and
inhibited the phosphorylation of FTY720. Furthermore, K145
inhibited the growth of U937 cells, mainly through apoptotic
effects. It is well documented that the activation of SphK/S1P
system leads to the activation of survival signaling pathways
including the ERK and Akt cascades. Moreover, like K145, TZD
analogues are known to be dual-pathway inhibitors [28,29].
Consistent with this notion, K145 significantly inhibited the
phosphorylation of ERK and Akt upon treatment of U937 cells
and the deactivation of ERK and Akt might contribute to its
Table 1. HINT scores of the docked molecules into SphK1
and SphK2.
HINT Scoresa
Ligand SphK2 SphK1
K145 3011 1506
FTY720 2751 2347
(R)-FTY720-OMe 1878 138
SG-12 1876 1626
ABC294640 153 273
Trans-12b 218 2985
SK1-I 679 2080
aPrevious studies have shown that ,515 score units correspond to
DDG=21.0 kcal/mol [49]. In the absence of a reference point from a calibration
for this specific biomolecular system, the HINT score differences between
ligands and/or between SphK1 and SphK2 are more meaningful than their
specific values.
doi:10.1371/journal.pone.0056471.t001
Figure 7. Docking results of K145 to SphKs. Binding mode of K145 in SphK1 (A) and SphK2 (B). K145 is shown as sticks with carbon in green,
while the interacting residues of both kinases are shown as sticks with carbons depicted in cyan. For simplicity, hydrogens are only shown on residues
forming hydrogen-bonding interactions with K145.
doi:10.1371/journal.pone.0056471.g007
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apoptotic effects as these two signalling pathways have been closely
linked to apoptosis in leukemia cells. Most importantly, K145 was
shown to significantly suppress the growth of U937 tumors in nude
mice through both intraperitoneal and oral administration without
apparent toxicity, thus attesting to its oral bioavailability and in vivo
anti-tumor actiivty. The use of a syngeneic tumor model further
confirmed that K145 significantly inhibited the growth of JC
tumor cells in BALB/c mice at both 20 and 35 mg/kg doses, again
without apparent toxicity. These results encourage further
optimization of K145 as a novel lead compound to develop more
potent and selective SphK2 inhibitors. Our results may also
suggest that development of novel thiazolidine-based inhibitors
may provide effective compounds as anticancer agents.
Materials and Methods
Chemistry
Reagents and solvents were obtained from commercial suppliers
and used as received unless otherwise indicated. All reactions were
carried out under inert atmosphere (N2) unless otherwise noted.
Reactions were monitored by thin-layer chromatography (TLC)
(precoated silica gel 60 F254 plates, EMD Chemicals) and
visualized with UV light or by treatment with Phosphomolybdic
acid (PMA). Flash chromatography was performed on silica gel
(200–300 mesh, Fisher Scientific) using solvents as indicated.
1HNMR and 13CNMR spectra were routinely recorded on Bruker
ARX 400 spectrometer. The NMR solvent used was CDCl3 or
DMSO-d6 as indicated. Tetramethylsilane (TMS) was used as
internal standard. The purity of target compound was determined
by elemental analysis.
5-(4-butoxybenzyl)-2,2-dimethyl-1,3-dioxane-4,6-dione
(10). To a stirred solution of 4-butoxybenzaldehyde (891.0 mg,
5.0 mmol) and Meldrum’s acid (720.0 mg, 5.0 mmol) in EtOH
(5.0 mL) was added piperidine (two drops). The resulting solution
was stirred at room temperature overnight and suction filtration
gave a light yellow solid (731.0 mg). To the mixture of the yellow
solid and acetic acid (3.0 mL) in CH2Cl2 (20.0 mL) was added
sodium borohydride (314.0 mg, 8.4 mmol) at 0uC. The resulting
solution was stirred at room temperature for 1 h, diluted with
CH2Cl2 (30.0 mL) and washed with brine and water. The organic
layer was then dried over anhydrous Na2SO4. After filtration, the
mixture was concentrated under vacuum and the residue was
purified by flash column chromatography (hexane/acetone = 5/2)
to give 10 as a light yellow solid, 28% yield. 1H NMR (400 MHz,
Figure 8. K145 suppresses the growth of U937 xenograft in nude mice. BALB/c-nu mice (n = 7) with palpable U937 xenograft were treated
daily with vehicle, tamibarotene (15 mg/kg), or K145 (15 mg/kg) for 17 days by i.p. injection. A) After treatment, animals were sacrificed and tumors
were removed and weighed and the TGI was calculated; B) Tumor volumes were measured every other day during the treatment course; C) Animal
weights were measured every other day during treatment course. Data are expressed as mean value 6 SD. *P,0.05 compared to control group.
doi:10.1371/journal.pone.0056471.g008
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CDCl3): 7.23–7.21 (d, J= 8.6 Hz, 2H), 6.82–6.79 (d, J = 8.6 Hz,
2H), 3.92 (t, J = 6.5 Hz, 2H), 3.71 (t, J = 4.8 Hz, 1H), 3.44–3.43
(d, J= 4.8 Hz, 2H), 1.76–1.70 (m, 5H), 1.50–1.44 (m, 5H), 0.96 (t,
J = 7.4 Hz, 3H).
4-butoxyphenyl-3-propanal (11). To a solution of com-
pound 10 (368.0 mg, 1.2 mmol) in THF (7.0 mL) was added Et3N
(0.3 mL, 2.4 mmol) followed by phenylsilane (0.4 mL, 3.6 mmol).
The resulting solution was stirred for 2 h at room temperature.
Water was added to the solution and stirred for 15 min. The
reaction mixture was diluted with diethyl ether (15.0 mL) and
washed with water and brine. The organic layer was dried over
anhydrous Na2SO4 overnight. After filtration, the filtrate was
concentrated and the residue was purified by flash column
chromatography (hexane/acetone = 10/1) to give 11 as a light
colorless oil, 81% yield. 1H NMR (400 MHz, CDCl3): 9.81 (t,
J = 1.5 Hz, 1H), 7.10–7.08 (d, J = 8.6 Hz, 2H), 6.83–6.81 (d,
J = 8.6 Hz, 2H), 3.93 (t, J= 6.5 Hz, 2H), 2.90 (t, J= 7.5 Hz, 1H),
2.76–2.72 (m, 2H), 1.77–1.71 (m, 2H), 1.55–1.43 (m, 2H), 0.97 (t,
J = 7.4 Hz, 3H).
t-butyl 2-bromoethylcarbamate (13). To a stirred suspen-
sion of bromoethylamine hydrobromide (20.5 g, 100.0 mmol),
(Boc)2O (21.8 g, 100.0 mmol) in CH2Cl2 (200.0 mL) was added
triethylamine (13.9 mL, 100.0 mmol) dropwise at 0uC. After
addition, the mixture was stirred at room temperature overnight,
and then water was added. The separated CH2Cl2 layer was
washed with brine, and dried over anhydrous Na2SO4. Removal
of the solvents gave 13 as colorless oil, 89% yield. 1H NMR
(400 MHz, CDCl3): d 4.95 (s, 1H), 3.54–3.53 (m, 2H), 3.47–3.45
(m, 2H), 1.45(s, 9H).
t-Butyl 2-(2,4-dioxothiazolidin-3-yl)-ethylcarbamate
(14). A mixture of thiazolidine-2,4-dione (7.9 g, 68.0 mmol),
13 (17.9 g, 80.0 mmol), K2CO3 (11.1 g, 92.0 mmol), and TBAI
(2.5 g, 6.8 mmol) in acetone (100.0 mL) was stirred at 40uC for
10 h. The reaction mixture was cooled to room temperature and
filtered through a short bed of celite. The filtrate was concentrated
under vacuum and the residue was purified by flash chromatog-
raphy (Hexane/EtOAc = 4/1 to 2/1) to give 14 as white solid,
70% yield. 1H NMR (300 MHz, CDCl3): d 3.94 (s, 2H), 3.78–3.74
(t, J = 6.0 Hz, 2H), 3.40–3.34 (t, J = 6.0 Hz, 2H), 1.43(s, 9H).
3-(2-aminoethyl)-5-(3-(4-
butoxyphenyl)propylidene)thiazolidine-2,4-dione (7). A so-
lution of 14 (2.0 g, 7.7 mmol), 4-butoxyphenyl-3-propanal (1.9 g,
7.7 mmol) and piperidine (0.2 mL, 3.6 mmol) in EtOH (60.0 mL)
was stirred at room temperature overnight. The solvents were
Figure 9. K145 suppresses the growth of JC xenograft in BALB/c mice. BALB/c mice (n = 8) with palpable JC xenograft were treated daily
with vehicle or K145 (20 mg/kg and 35 mg/kg) for 15 days by i.p. injection. A) Tumor volumes were measured every other day; B) After treatment,
animals were sacrificed and tumors were removed and weighed; C) The S1P and K145 levels in the tumor samples from vehicle and treatment
(20 mg/kg) groups (n = 4) were measured by ESI-MS/MS; D) Images of tumor samples from control and treatment groups (n = 7 for each group) after
the experiments; E) Tumor samples (20 mg/kg and control groups) were analyzed by Western blot. Data are expressed as mean value 6 SEM.
*P,0.05 compared to control group.
doi:10.1371/journal.pone.0056471.g009
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removed under vacuum and the residue was purified by flash
column chromatography (hexane/EA = 8/1) to give t-butyl 2-(5-
(3-(4-butoxyphenyl)propylidene)-2,4-dioxothiazolidin-3-yl)ethyl-
carbamate as a white solid, 60% yield. 1H NMR (400 MHz,
CDCl3): 7.10–7.06 (m, 3H), 6.85–6.80 (d, J = 8.6 Hz, 2H), 4.72 (s,
1H), 3.94 (t, J = 6.5 Hz, 2H), 3.81 (t, J = 5.5 Hz, 2H), 3.39–3.38
(m, 2H), 2.78 (t, J = 7.4 Hz, 2H), 2.53–2.48 (q, J= 7.6 Hz, 2H),
1.80–1.72 (m, 2H), 1.49–1.44 (m, 2H), 1.40 (s, 9H), 0.97 (t,
J = 7.4 Hz, 3H). To a stirred solution of t-butyl 2-(5-(3-(4-
butoxyphenyl)propylidene)-2,4-dioxothiazolidin-3-yl)ethylcarba-
mate (2.3 g, 4.7 mmol) in EtOAc (20.0 mL) was added 4 M HCl
in dioxane (6.0 mL), the solution was stirred at room temperature
for 5 h. The precipitate was collected by filtration to give the HCl
salt of 7 as white solid, 75% yield. 1H NMR (400 MHz, DMSO-
d6): 8.08 (brs, 3H), 7.15–7.13 (d, J= 8.5 Hz, 2H), 7.01 (t,
J = 7.4 Hz, 1H), 6.86–6.84 (d, J = 8.5 Hz, 2H), 3.92 (t,
J = 6.4 Hz, 2H), 3.83 (t, J= 6.0 Hz, 2H), 3.00 (m, 2H), 2.76 (t,
J = 7.3 Hz, 2H), 2.53–2.48 (m, 2H), 1.69–1.64 (m, 2H), 1.45–1.39
(m, 2H), 0.92 (t, J= 7.3 Hz, 3H); 13C NMR (100 MHz, DMSO-
d6): 167.5, 164.4, 157.1, 137.3, 131.9, 129.2, 125.1, 114.3, 66.9,
36.5, 32.9, 32.1, 30.7, 18.6, 13.6. Anal. (C18H25ClN2O3S) Calcd.
C: 56.17%, H: 6.55%, N: 7.28%, S: 8.33%; found C: 55.91%, H:
6.69%, N: 7.14%, S: 8.16%.
Homology and Molecular Modeling
Human SphK1 (Accession: Q9NYA1) and SphK2 (Accession:
NP_001191088) sequences were obtained from the NCBI
database (www.ncbi.nih.gov/protein/). A Position Specific Iterat-
ed BLAST [42,43] search against the database of Protein Data
Bank proteins identified a kinase – diacylgycerol kinase from
Bacillus anthracis str. Sterne (PDB ID: 3T5P), as the closest match to
both proteins with ,25% identity and ,46% homology in the
aligned regions to both isoforms of SphK. Sequence alignments of
each SphK1 and SphK2 with 3T5P were performed using
CLUSTALX2 [53]. Unaligned regions in both the proteins were
deleted. A total of 100 homology models for each isoform were
generated based on these alignments, using MODELLER 9v10
[54]. The top 5 models for each kinase with the lowest DOPE
(Discrete Optimized Protein Energy) scores and molpdf scores (a
MODELLER object function score) and with GA341 [55] scores
closest to 1 were chosen for further refinement. The side chains for
each model were optimized using SCWRL (dunbrack.fcc.edu/
scwrl4/). Hydrogens were added to these top models using SYBYL
8.1 (www.tripos.com) and subsequently subjected to Powell
minimization for 10000 iterations in the Tripos force field with
a 0.005 kcal/mol-A˚ termination gradient. The quality of mini-
mized models was evaluated using MOLPROBITY (molprobity.-
Figure 10. K145 suppresses the growth of U937 tumors in nude mice by oral administration. BALB/c-nu mice (n = 7) with palpable U937
xenograft were treated daily with vehicle, tamibarotene (20 mg/kg), or K145 (50 mg/kg) for 15 days by oral gavage. After treatment, animals were
sacrificed and tumors were removed, weighed and images were taken. A) Tumor weight and TGI comparison; B) Images of tumor samples from
control and treatment groups (n = 7 for each group) after the experiments; C) Tumor volumes were measured every other day; D) Animal weights
were measured every other day. Data are expressed as mean value 6 SEM. *P,0.05 compared to control group.
doi:10.1371/journal.pone.0056471.g010
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biochem.duke.edu/), which performs an all-atom contact analysis
to give a ‘clashscore’ that is indicative of the number of serious
clashes (.0.4 A˚) per 1000 atoms. Poor side-chain rotamers and
unreasonable bond lengths and angles were checked. Ramachan-
dran plots were also generated using MOLPROBITY to check the
backbone-geometry of the models. Atom clashes and bad bond
lengths and angles were optimized with further minimization.
Sphingosine, the natural substrate for both kinases, was docked
into the C4 domain (putative Sph binding domain, Leu163–
Phe197 for SphK1 and Cys329– Val363 for SphK2 [56]) of each
model, using GOLD v5.1 [48]. The docked poses were scored
using HINT [49].
The ‘‘best’’ model of both SphK1 and SphK2 was then chosen
based on its overall stability and its ability to accommodate
Sphingosine in its C4 domain. Model-044 was the best model for
SphK1, with a clashscore of 3.2 (97th percentile) and with 96.8%
residues in allowed regions on Ramachandran plots. Model-055
was the best model for SphK2, with a clashscore of 2.03 (99th
percentile) and with 98.5% residues in allowed regions on
Ramachandran plots.
The optimized models of both SphK1 and SphK2 were used for
the docking studies. The structures of inhibitors were sketched
using SYBYL v8.1, and subjected to minimization to obtain low
energy structures. The docking simulations were performed using
GOLD v5.1. The binding site was defined to encompass all atoms
within 20 A˚ of CA of Asp178 of SphK1 (Asp344 of SphK2). Fifty
solutions for each inhibitor molecule were generated with a
protein hydrogen-bond constraint that the carboxylate of Asp178
of SphK1 (Asp344 of SphK2) forms a hydrogen bond with ligand,
since the Asp is important for recognition of Sphingosine [48]. The
docked poses were scored using HINT. The poses with the best
HINT scores were complexed with the protein and the protein-
ligand complex was subjected to minimization, to remove steric
clashes and get an induced-fit model. The binding modes of the
ligands after minimization were re-scored using HINT.
Cell Culture
Human leukemia U937 cells and murine JC mammary cells
were obtained from American Type Culture Collection (ATCC,
Manassas, VA) and cultured in RPMI 1640 medium (Life
Technologies, Inc., Grand Island, NY) supplemented with 10%
(v/v) of heat-inactivated fetal bovine serum (FBS, Hyclone, Logan,
UT). Cells were maintained at 37uC in a fully humidified
atmosphere containing 5% CO2. All reagents were prepared
and used as recommended by their suppliers.
SphK Activity
Lysates from cells overexpressing SphK1 or SphK2 were used
for determining the effects of inhibitors on enzyme activity [11].
SphK1 activity was determined in the presence of 5 mM
sphingosine and [c-32P]ATP (10 mCi, 1 mM) containing MgCl2
(10 mM) in 0.25% Triton X-100, which inhibits SphK2, as
described previously [11]. SphK2 activity was determined with
sphingosine added as a complex with 4 mg/ml BSA and
[c-32P]ATP in the presence of 1 M KCl, conditions in which
SphK2 activity is optimal and SphK1 strongly inhibited [18].
Ceramide Kinase Assay
Ceramide and human recombinant ceramide kinase (CERK)
were obtained from BPS bioscience, Kinase-Glo luminescent assay
regents were obtained from Promega. Assays were carried out on
96 wells plate at 50 mL scale in triplicate. For each well,
compounds, 15 mM ceramide (prepared freshly according to the
manufacturer’s instruction), and 40 ng CERK were incubated at
RT for 5 min, the reaction was started by addition of ATP (5 mM
final concentration). Incubated at 37uC for 25 min, 50 mL of
Kinase-Glo luminescent regent was added and incubated at RT
for 10 min. The luminescence was recorded by a FlexStation 3
plate reader (Molecular Devices, CA).
Lipidomics Analysis
Four million U937 cells were treated by K145 for 3 h. Cells
were collected and washed with PBS and analyzed by ESI-MS/
MS. For influence of FTY720-P formation, 4 million U937 cells
were incubated with K145 together with 1 mM FTY720 for 3 h,
then cells was collected and washed with PBS and analyzed by
LC-MS/MS as described previously [57].
Cell Proliferation Assays
U937 cells (20,000 cells/well) were plated into 96-well plate and
treated with K145 for 72 h. Then 10 mL of MTT [3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 5 mg/mL
in PBS] was added and cells incubated for an additional 2 h at
37uC in a fully humidified atmosphere containing 5% CO2. After
centrifuge, medium (170 mL) was removed and DMSO (100 mL)
was added to each well. The absorbance was read by a FlexStation
3 plate reader (Molecular Devices, CA) at a wavelength of
570 nm. Values were expressed as a percentage relative to those
obtained in untreated controls.
Apoptosis Assay
U937 (16106) cells were treated with K145 at indicated
concentrations and indicated intervals, then cells were collected
and washed twice with cold PBS. Cells were resuspended in buffer
containing 10 mM HEPES [N-2-hydroxyethylpiperazine-N’-2-
ethanesulfonic acid]/NaOH, pH 7.4, 140 mM NaOH, and
2.5 mM CaCl2. The cells were incubated with annexin V-
fluorescein isothiocyanate (FITC) (BD PharMingen, San Diego,
CA) and propidium iodide (PI) for 15 min at room temperature
per manufacturer’s instruction. The samples were analyzed by
flow cytometry using a Beckton Dickinson FACSCanto machine
within 1 h to determine the percentage of cells displaying annexin
V-FITC staining (early apoptosis) or both annexin V-FITC and PI
staining (late apoptosis).
Western Blotting
U937 Cells (26105/mL) were treated with K145 at indicated
concentration for 1 h in the presence of 10% FBS. Cells were lysed
by sonication in sample buffer [62.5 mM Tris base (pH 6.8), 2%
SDS, 50 mM DTT, 10% glycerol, 0.1% bromphenol blue, and
5 mg/mL each chymostatin, leupeptin, aprotinin, pepstatin, and
soybean trypsin inhibitor] and boiled for 5 min. For analysis of
phospho-proteins, 1 mM of sodium orthovanadate and sodium
pyrophosphate was added to the sample buffer. Proteins were
collected from the supernatant after centrifugation at 12,8006g for
5 min, and quantified using Coomassie Protein Assay Reagent
(Pierce, Rockford, IL). Equal amounts of protein (30.0 mg) were
separated by SDS-PAGE on 4–10% tris/glycine gel (Bio-Rad) and
electrotransferred onto a PVDF membrane (Bio-Rad). For blotting
phosphoproteins, no SDS was included in the transfer buffer. The
blots were blocked with 5% nonfat dry milk in TBS-Tween 20
(0.1%) at room temperature for 1 hour and probed with the
appropriate dilution of primary antibody overnight at 4uC. The
blots were washed twice with TBS-Tween 20 for 15 min and then
incubated with a 1:2000 dilution of horseradish peroxidase-
conjugated secondary antibody (Kirkegaard & Perry, Gaithers-
burg, MD) in 5% nonfat dry milk/TBS-Tween 20 at room
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temperature for 1 h. After washing twice in TBS-Tween 20 for
15 min, the immunopositive bands were visualized with Western
Blot Chemiluminescence Reagent (NEN Life Science Products,
Boston, MA). Where indicated, the blots were re-probed with
antibodies against GAPDH to ensure equal loading and transfer of
proteins. The following antibodies were used as primary antibod-
ies: Cell Signaling, MA: phospho-p44/42 MAPK (Thr202/
Tyr204) antibody (1:1000, rabbit polyclonal), p44/42 MAPK
antibody (1:1000, rabbit polyclonal), phospho-Akt (Ser473) anti-
body (1:1000, rabbit polyclonal), Santa Cruz, CA: Akt1/2/3 (H-
136) (1:1000, rabbit polyclonal).
In vivo Antitumor Evaluations
All experiments involving animals were carried out in strict
accordance with the recommendations in the Guidelines and
Regulations of Institutional Animal Care and Use Committee
(IACUC) of the Virginia Commonwealth University (VCU). The
protocol was approved by the Committee on the Ethics of Animal
Experiments of VCU (IACUC Number: AM10206). For U937
xenografts studies, female BALB/c-nu nude mice (Charles River,
NC) were maintained under specific pathogen-free conditions.
Human leukemia U937 cells (16 106, ATCC, Manassas, VA) in
logarithmic growth phase were implanted in the right flanks of
each mouse. Once the U937 xenografts reached a palpable size,
mice were randomly assigned to control group or treatment
groups (n = 7). Compound K145 and Tamibarotene were
administered via intraperitoneal (i.p.) injection at 15 mg/kg dose
daily for 17 days. For oral administration, K145 and Tamibar-
otene were administered at 50 mg/kg and 20 mg/kg, respectively,
by oral gavage. Body weight and tumor size were measured every
three days and the tumor volume was calculated using the
equation V = ab2/2, where a and b are the longest and shortest
diameters, respectively. At the end of treatment, mice were
sacrificed and tumors were collected and weighted. Tumor growth
inhibition (TGI) was calculated as TGI = (Mv – Md)/Mv where Mv
is the mean tumor weight of vehicle-treated group and Md is the
mean tumor weight of drug-treated group.
For syngeneic cancer studies, the transformed mouse JC
mammary adenocarcinoma cells (1 6 106, ATCC, Manassas,
VA) were implanted subcutaneously in immunocompetent BALB/
c mice (18–20 g, Charles River, NC). Once the JC xenografts were
detectable, mice were then randomly grouped into control or
treatment groups (n = 8). K145 was given (20 mg/kg and 35 mg/
kg) daily for 15 days. Body weights and volume of tumors were
measured every other day, and tumor volume (V) was again
calculated. At the end of treatment, mice were sacrificed, tumors
were collected and weighted. Tumor samples were homogenized
in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA,
1% Triton X100, 0.25% sodium deoxycholate, 0.1% SDS, 1 mM
PMSF, pH 7.4) supplemented with protease and phosphatase
inhibitor cocktail (Roche) for Western blot analysis.
Acknowledgments
We thank Dr. Sheldon Milstien and Dr. Santiago Lima from the
Department of Biochemistry and Molecular Biology, VCU for helpful
discussions.
Author Contributions
Conceived and designed the experiments: SS SZ. Performed the
experiments: KL TLG NH HP JA. Analyzed the data: WX GEK SG.
Wrote the paper: KL GEK SS SZ.
References
1. Spiegel S, Milstien S (2003) Sphingosine-1-phosphate: an enigmatic signalling
lipid. Nat Rev Mol Cell Biol 4: 397–407.
2. Pitson SM (2011) Regulation of sphingosine kinase and sphingolipid signaling.
Trends Biochem Sci 36: 97–107.
3. Kohama T, Olivera A, Edsall L, Nagiec MM, Dickson R, et al. (1998) Molecular
cloning and functional characterization of murine sphingosine kinase. J Biol
Chem 273: 23722–23728.
4. Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, et al. (2000) Molecular
cloning and functional characterization of a novel mammalian sphingosine
kinase type 2 isoform. J Biol Chem 275: 19513–19520.
5. Takabe K, Paugh SW, Milstien S, Spiegel S (2008) ‘‘Inside-out’’ signaling of
sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 60: 181–195.
6. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, et al. (2009)
Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate.
Science 325: 1254–1257.
7. Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, et al. (2010)
Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase
TRAF2. Nature 465: 1084–1088.
8. Hannun YA, Obeid LM (2008) Principles of bioactive lipid signalling: lessons
from sphingolipids. Nat Rev Mol Cell Biol 9: 139–150.
9. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, et al. (1996)
Suppression of ceramide-mediated programmed cell death by sphingosine-1-
phosphate. Nature 381: 800–803.
10. Pyne S, Bittman R, Pyne NJ (2011) Sphingosine kinase inhibitors and cancer:
seeking the golden sword of Hercules. Cancer Res 71: 6576–6582.
11. Siow D, Wattenberg B (2011) The compartmentalization and translocation of
the sphingosine kinases: mechanisms and functions in cell signaling and
sphingolipid metabolism. Crit Rev Biochem Mol Biol 46: 365–375.
12. Johnson KR, Becker KP, Facchinetti MM, Hannun YA, Obeid LM (2002)
PKC-dependent activation of sphingosine kinase 1 and translocation to the
plasma membrane. Extracellular release of sphingosine-1-phosphate induced by
phorbol 12-myristate 13-acetate (PMA). J Biol Chem 277: 35257–35262.
13. Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer S, et al. (2003) Sphingosine
kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem 278:
46832–46839.
14. Gault CR, Obeid LM (2011) Still benched on its way to the bedside: sphingosine
kinase 1 as an emerging target in cancer chemotherapy. Crit Rev Biochem Mol
Biol 46: 342–351.
15. Gao P, Smith CD (2011) Ablation of sphingosine kinase-2 inhibits tumor cell
proliferation and migration. Mol Cancer Res 9: 1509–1519.
16. Liu H, Toman RE, Goparaju SK, Maceyka M, Nava VE, et al. (2003)
Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis.
J Biol Chem 278: 40330–40336.
17. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, et al. (2005)
Sphingosine kinase-1 expression correlates with poor survival of patients with
glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of
glioblastoma cell lines. J Neuropathol Exp Neurol 64: 695–705.
18. Hait NC, Sarkar S, Le Stunff H, Mikami A, Maceyka M, et al. (2005) Role of
sphingosine kinase 2 in cell migration toward epidermal growth factor. J Biol
Chem 280: 29462–29469.
19. French KJ, Zhuang Y, Maines LW, Gao P, Wang W, et al. (2010) Pharmacology
and antitumor activity of ABC294640, a selective inhibitor of sphingosine
kinase-2. J Pharmacol Exp Ther 333: 129–139.
20. Beljanski V, Lewis CS, Smith CD (2011) Antitumor activity of sphingosine
kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma
xenografts. Cancer Biol Ther 11: 524–534.
21. Strub GM, Paillard M, Liang J, Gomez L, Allegood JC, et al. (2011)
Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria
interacts with prohibitin 2 to regulate complex IV assembly and respiration.
FASEB J 25: 600–612.
22. French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, et al. (2006) Antitumor
activity of sphingosine kinase inhibitors. J. Pharmacol Exp Ther 318: 596–603.
23. Kennedy AJ, Mathews TP, Kharel Y, Field SD, Moyer ML, et al. (2011)
Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and
reduction of sphingosine 1-phosphate in human leukemia cells. J Med Chem 54:
3524–3548.
24. Paugh SW, Paugh BS, Rahmani M, Kapitonov D, Almenara JA, et al. (2008) A
selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic
targets in human leukemia. Blood 112: 1382–1391.
25. Kim JW, Kim YW, Inagaki Y, Hwang YA, Mitsutake S, et al. (2005) Synthesis
and evaluation of sphingoid analogs as inhibitors of sphingosine kinases. Bioorg
Med Chem 13: 3475–3485.
26. Lim KG, Sun C, Bittman R, Pyne NJ, Pyne S (2011) (R)-FTY720 methyl ether is
a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2
expression in HEK 293 cells and actin rearrangement and survival of MCF-7
breast cancer cells. Cell Signal 23: 1590–1595.
27. Raje MR, Knott K, Kharel Y, Bissel P, Lynch KR, et al. (2012) Design, synthesis
and biological activity of sphingosine kinase 2 selective inhibitors. Bioorg Med
Chem 20: 183–194.
Development of K145 as a SphK2 Inhibitor
PLOS ONE | www.plosone.org 12 February 2013 | Volume 8 | Issue 2 | e56471
28. Li Q, Al-Ayoubi A, Guo T, Zheng H, Sarkar A, et al. (2009) Structure-activity
relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazol-
idine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors.
Bioorg Med Chem Lett 19: 6042–6046.
29. Liu K, Rao W, Parikh H, Li Q, Guo TL, et al. (2012) 3,5-Disubstituted-
thiazolidine-2,4-dione analogs as anticancer agents: Design, synthesis and
biological characterization. Eur J Med Chem 47: 125–137.
30. Baell JB, Holloway GA (2010) New substructure filters for removal of pan assay
interference compounds (PAINS) from screening libraries and for their exclusion
in bioassays. J Med Chem 53: 2719–2740.
31. Tomasic T, Masic LP (2009) Rhodanine as a Privileged Scaffold in Drug
Discovery. Curr Med Chem 16: 1596–1629.
32. Mendgen M, Steuer C, Klein CD (2012) Privileged scaffolds or promiscuous
binders: A comprehensive study on rhodanines and related heterocycles in
medicinal chemistry. J Med Chem 55: 743–753.
33. Knight SD, Adams ND, Burgess JL, Chaudhari AM, Darcy MG, et al. (2010)
Discovery of GSK2126458, a highly potent inhibitor of PI3K and the
mammalian target of rapamycin. ACS Med Chem Lett 1: 39–43.
34. Cuvillier O, Levade T (2001) Sphingosine-1-phosphate antagonizes apoptosis of
human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO
from mitochondria. Blood 98: 2828–2836.
35. Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S (2003) The
immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
FEBS Lett 554: 189–193.
36. Kharel Y, Raje M, Gao M, Gellett AM, Tomsig JL, et al. (2012) Sphingosine
kinase type 2 inhibition elevates circulating sphingosine-1-phosphate. Biochem J
447: 149–157.
37. Shu X, Wu W, Mosteller RD, Broek D (2002) Sphingosine kinase mediates
vascular endothelial growth factor-induced activation of ras and mitogen-
activated protein kinases. Mol Cell Biol 22: 7758–7768.
38. Osawa Y, Banno Y, Nagaki M, Brenner DA, Naiki T, et al. (2001) TNF-a-
induced sphingosine-1-phosphate inhibits apoptosis through a phosphatidylino-
sitol-3-kinase/Akt pathway in human hepatocytes. J Immunol 167: 173–180.
39. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, et al. (2008)
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/
STAT pathways to leukemia. Leukemia 22: 686–707.
40. Grant.S. (2008) Cotargeting survival signaling pathways in cancer J Clin Invest
118: 3003–3006.
41. Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of
spatial restraints, J Mol Biol 234: 779–815.
42. Altschul SF, Madden TL, Scha¨ffer AA, Zhang J, Zhang Z, et al. (1997) Gapped
BLAST and PSI-BLAST: a new generation of protein database search
programs. Nucleic Acids Res 25: 3389–3402.
43. Altschul SF, Wootton JC, Gertz EM, Agarwala R, Morgulis A, et al. (2005)
Protein database searches using compositionally adjusted substitution matrices.,
FEBS J 272: 5101–5109.
44. Chen VB, Arendall III WB, Headd JJ, Keedy DA, Immormino RM, et al. (2010)
MolProbity: all-atom structure validation for macromolecular crystallography.
Acta Cystallographica D66: 12–21.
45. Yokota S, Taniguchi Y, Kihara A, Mitsutake S, Igarashi Y. (2004) Asp177 in C4
domain of mouse sphingosine kinase 1a is important for the sphingosine
recognition. FEBS Letters 578: 106–110.
46. Tonelli F, Lim KG, Loveridge C, Long J, Pitson SM, et al. (2010) FTY720 and
(S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its
proteasomal degradation in human pulmonary artery smooth muscle, breast
cancer and androgen-independent prostate cancer cells. Cell Signal 22: 1536–
1542.
47. Lim KG, Tonelli F, Li Z, Lu X, Bittman R, et al. (2011) FTY720 analogues as
sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism,
proteasomal degradation, and actin rearrangement in MCF-7 breast cancer
cells. J Biol Chem 286: 18633–18640.
48. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD (2003)
Improved protein-ligand docking using GOLD. Proteins: Structure, Function,
and Genetics 52: 609–623.
49. Kellogg GE, Abraham DJ (2000) Hydrophobicity: is LogP(o/w) more than the
sum of its parts? Eur J Med Chem 35: 651–661.
50. Marabotti A, Spyrakis F, Facchiano A, Cozzini P, Alberti S, et al. (2008) Energy-
based prediction of amino acid-nucleotide base recognition. J Comput Chem 29:
1955–1969.
51. Hamada Y, Yamada I., Uenaka M, Sakata T (1993) Method for preparing
benzoic acid derivatives. Patent US5214202.
52. Lee BD, French KJ, Zhuang Y, Smith CD (2003) Development of a syngeneic
in vivo tumor model and its use in evaluating a novel P-glycoprotein modulator,
PGP-4008. Oncol Res 14: 49–60.
53. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, et al. (2007)
Clustal W and Clustal X version 2.0. Bioinformatics 23: 2947–2948.
54. Maceyka M, Harikumar KB, Milstien S, Spiegel S (2012) Sphingosine-1-
phosphate signaling and its role in disease. Trends Cell Biol 22: 50–60.
55. Melo F, Sa´nchez R, Sali (2002) A Statistical potentials for fold assessment.
Protein Sci 11: 430–448.
56. Puneet P, Yap CT, Wong L, Lam Y, Koh DR, et al. (2010) SphK1 regulates
proinflammatory responses associated with endotoxin and polymicrobial sepsis.
Science 328: 1290–1294.
57. Shaner RL, Allegood JC, Park H, Wang E, Kelly S, et al. (2009) Quantitative
analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole
linear ion trap mass spectrometers. J Lipid Res 50: 1692–1707.
Development of K145 as a SphK2 Inhibitor
PLOS ONE | www.plosone.org 13 February 2013 | Volume 8 | Issue 2 | e56471
